Search
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigationalHydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalLupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesThallous chloride
go.drugbank.com/drugs/DB09316ApprovedWithdrawnThallous chloride (also known as Thallium(I) chloride) is a colourless solid intermediate in the isolation of thallium from its ores. It is created from the treatment of thallium(I) sulfate with hydrochloric acid. This solid crystallizes...
Products: THALLOUS CHLORIDE (Tl201) INJECTION 37 MBq/ml, Thalliumchlorid (201TI) CIS bio international Injektionslösung TL-201-S-1Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigationalPadeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, ...
TL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesErlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalThis finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amineFluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigationalFluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging.
Human thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalHuman thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.
Mixtures: EVICEL Fibrin Sealant (Human) Solution, 50-90 mg/ml, 800-1200 IU/mlAluminum zirconium trichlorohydrex gly
go.drugbank.com/drugs/DB11116ApprovedWithdrawnAluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.
Burosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalThis is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. … X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood.
Products: CRYSVITA ® SOLUCION PARA INYECCIÓN 10MG/ML, CRYSVITA® SOLUCIÓN PARA INYECCIÓN 20 MG/ML